Novel neural circuit biomarkers of major depression response to computer-augmented CBT (1R01MH110939 - 01A1)

Recruiting
99 years or below
All
61 participants needed

Brief description of study

This is a trial of an FDA-approved treatment for Major Depressive Disorder (MDD), computer-augmented cognitive behavioral therapy (CCBT), to examine novel potential neural circuit biomarkers of treatment response rather than to test efficacy. We will enroll 60 subjects, 18-60 years, who are seeking treatment for a current episode of Major Depressive Disorder. We also will enroll 40 healthy controls of a similar age/sex distribution. MDD subjects will be scheduled to receive CCBT at the first available appointment; all will be scheduled within 4 weeks. All subjects will have an fMRI at baseline; MDD subjects will have an fMRI after treatment. MDD subjects scheduled to start CCBT treatment after 3 weeks will complete an additional fMRI before they begin CCBT.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 832295

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.